Search Results 1281-1290 of 16770 for monoclonal antibody

1. Clinical trials - Oncology (Medical)

   This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and ...

2. Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer - Mayo Clinic

   * Patients with prior hypersensitivity to monoclonal antibodies (mAb) * Women who are pregnant or breastfeeding * Patients who received prior treatment with ...

3. Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy - Mayo Clinic

   Patients must be tested for hepatitis B virus (HBV), hepatitis B surface antigen (HBsAg+) and hepatitis C (HCV) antibody within 6 weeks of registration.

4. A Study to Evaluate the Effectiveness of M7824 Monotherapy in Locally Advanced or Metastatic Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) - Mayo Clinic

   ... antibodies. Prior therapy with any antibody or inhibitors targeting the TGF-β/TGF-β receptor pathway. Anticancer treatment within 21 days before the start ...

5. Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma - Mayo Clinic

   ... monoclonal plasma cells in the bone marrow ... antibodies to hepatitis B ... antibody positive or HCV-ribonucleic acid [RNA] quantitation positive) ...

6. A Study of KRN23 in Adult Subjects with Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome - Mayo Clinic

   Have used a therapeutic monoclonal antibody, including KRN23, within 90 days prior to Screening or have a history of allergic or anaphylactic reactions to any ...

7. Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients

   Previous in vivo exposure to monoclonal antibodies for biological therapy in the 6 weeks before enrollment. Planned administration of growth factors or ...

8. A Study to Evaluate the Safety and Effectiveness of AB928-Based Treatment Combinations to Treat Patients with Metastatic Colorectal Cancer - Mayo Clinic

   antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain Barré syndrome, or multiple sclerosis - Exclusion Criteria for Cohorts A and B ...

9. Safety and Efficacy of ALLO-715 and ALLO-647 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) - Mayo Clinic

   ... antibody (ALLO-647)-containing regimen in 43 patients with relapsed/refractory multiple myeloma as part A of the ongoing first-in-human phase 1 UNIVERSAL trial.

10. A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM - Mayo Clinic

    Chemotherapy, biologic therapy (i.e., small molecular inhibitors), monoclonal antibodies ... antibody on a shorter frequency (i.e., every two weeks), then the ...